{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T22:54:50Z","timestamp":1649112890104},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2009,4,25]],"date-time":"2009-04-25T00:00:00Z","timestamp":1240617600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ophthalmologe"],"published-print":{"date-parts":[[2009,5]]},"DOI":"10.1007\/s00347-009-1933-1","type":"journal-article","created":{"date-parts":[[2009,4,23]],"date-time":"2009-04-23T21:08:10Z","timestamp":1240520890000},"page":"397-398","source":"Crossref","is-referenced-by-count":1,"title":["Bevacizumab goes anterior"],"prefix":"10.1007","volume":"106","author":[{"given":"C.","family":"Cursiefen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,4,25]]},"reference":[{"key":"1933_CR1","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1089\/lrb.2008.6348","volume":"6","author":"Regenfuss","year":"2008","unstructured":"Regenfuss B, Bock F, Parthasarathy A, Cursiefen C (2008) Corneal (lymph)angiogenesis -from bedside to bench and back: a tribute to Judah Folkman. Lymphat Res Biol 6:191\u2013201","journal-title":"Lymphat Res Biol"},{"key":"1933_CR2","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1167\/iovs.03-1380","volume":"45","author":"Cursiefen","year":"2004","unstructured":"Cursiefen C, Maruyama K, Liu Y et al (2004) Inhibition of hemangiogenesis and lymphangiogenesis after normal-risk corneal transplantation by neutralizing VEGF promotes graft survival. Invest Ophthalmol Vis Sci 45:2666\u20132673","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1933_CR3","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/archopht.126.1.71","volume":"126","author":"Bachmann","year":"2008","unstructured":"Bachmann B, Bock F, Wiegand S et al (2008) VEGF-A-neutralization after high-risk corneal transplantation promotes graft survival. Arch Ophthalmol 126:71\u201377","journal-title":"Arch Ophthalmol"},{"key":"1933_CR4","doi-asserted-by":"crossref","unstructured":"Bachmann B, Luetjen-Drecoll E, Bock F et al (2009) Transient postoperative VEGF-neutralisation improves graft survival in corneas with partly regressed inflammatory neovascularisation. Br J Ophthalmol (in press)","DOI":"10.1136\/bjo.2008.145128"},{"key":"1933_CR5","doi-asserted-by":"crossref","unstructured":"Regenfuss B, Bock F, Bachmann B et al (2009) Topische antiangiogene Therapie an der Hornhaut: Sicherheit und Effektivit\u00e4t. Ophthalmologe \u25a0\u25a0\u25a0","DOI":"10.1007\/s00347-009-1934-0"},{"key":"1933_CR6","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1016\/j.ophtha.2008.06.009","volume":"115","author":"Grewal","year":"2008","unstructured":"Grewal DS, Jain R, Kumar H, Grewal SP (2008) Evaluation of subconjunctival bevacizumab as an adjunct to trabeculectomy a pilot study. Ophthalmology 115:2141\u20132145","journal-title":"Ophthalmology"},{"key":"1933_CR7","doi-asserted-by":"crossref","unstructured":"L\u00fcke J, L\u00fcke M, Grisanti S (2009) Antiangiogene Therapie bei neovaskul\u00e4rem Glaukom und nach Filterkissenchirurgie. Ophthalmologe \u25a0\u25a0\u25a0","DOI":"10.1007\/s00347-009-1940-2"},{"key":"1933_CR8","doi-asserted-by":"crossref","unstructured":"Leippi S, Grehn F, Geerling G (2009) Antiangiogene Therapie bei Pterygium-Rezidiven. Ophthalmologe \u25a0\u25a0\u25a0","DOI":"10.1007\/s00347-009-1936-y"},{"key":"1933_CR9","doi-asserted-by":"crossref","unstructured":"Heindl LM, Hofmann TN, Knorr HL et al (2009) Intraocular lymphangiogenesis in malignant melanomas of the ciliary body with extraocular extension. Invest Ophthalmol Vis Sci (Epub ahead of print)","DOI":"10.1167\/iovs.08-2935"},{"key":"1933_CR10","doi-asserted-by":"crossref","unstructured":"Cursiefen C, Bock F, Horn FK et al (2009) GS-101 antisense oligonucleotide eye drops inhibit corneal neovascularization: interim results of a randomized phase II trial. Ophthalmology (in press)","DOI":"10.1016\/j.ophtha.2009.04.016"},{"key":"1933_CR11","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1167\/iovs.06-0570","volume":"48","author":"Bock","year":"2007","unstructured":"Bock F, Onderka J, Dietrich T et al (2007) Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis. Invest Ophthalmol Vis Sci 48:2545\u20132552","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1933_CR12","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s00417-007-0684-4","volume":"246","author":"Bock","year":"2008","unstructured":"Bock F, K\u00f6nig Y, Kruse FE et al (2008) Bevacizumab (Avastin\u00ae) eye drops inhibit corneal neovascularisation. Graefes Arch Clin Exp Ophthalmol 246:281\u2013284","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1933_CR13","doi-asserted-by":"crossref","unstructured":"Bock F, Onderka J, Rummelt C et al (2009) Safety profile of topical VEGF-neutralization at the cornea. Invest Ophthalmol Vis Sci (Epub ahead of print)","DOI":"10.1167\/iovs.07-1129"}],"container-title":["Der Ophthalmologe"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-009-1933-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00347-009-1933-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-009-1933-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T13:50:55Z","timestamp":1559051455000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00347-009-1933-1"}},"subtitle":["Antiangiogene Therapie am vorderen Augenabschnitt"],"short-title":[],"issued":{"date-parts":[[2009,4,25]]},"references-count":13,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009,5]]}},"alternative-id":["1933"],"URL":"https:\/\/doi.org\/10.1007\/s00347-009-1933-1","relation":{},"ISSN":["0941-293X","1433-0423"],"issn-type":[{"value":"0941-293X","type":"print"},{"value":"1433-0423","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,4,25]]}}}